LOGO
LOGO

Will Unicycive's OLC Clear The FDA Hurdle And Become An Attractive New Option For Hyperphosphatemia?

By Prabha Kurup   ✉  | Published:  | Google News Follow Us  | Join Us
fdaapprovel 11062026 lt

The month of June is set to be a crucial period for Unicycive Therapeutics Inc. (UNCY), as it stands on the threshold of a key regulatory event that could significantly shape its near-term prospects.

The FDA decision on the company's lead drug candidate, Oxylanthanum Carbonate, or OLC in short, proposed for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis, is due on June 29, 2026.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update - Jun 08-12, 2026

June 12, 2026 17:14 ET
Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.

RELATED NEWS